Please use this identifier to cite or link to this item:
Title: Superior effect of MP-AzeFlu than azelastine or fluticasone propionate alone on reducing inflammatory markers
Author: Roca i Ferrer, Jordi
Pujols Tarrés, Laura
Pérez-González, Maria
Alobid, Isam
Callejas, Francisco de Borja
Vicens Artés, Sònia
Fuentes Prado, Mireya
Valero, Antonio
Picado Vallés, César
Castor, Dennis
Nguyen, DucTung
Mullol i Miret, Joaquim
Keywords: Rinitis
Cèl·lules epitelials
Epithelial cells
Issue Date: 18-Dec-2018
Publisher: BioMed Central
Abstract: Background: MP-AzeFlu, intranasal formulation of azelastine hydrochloride (AZE) and fluticasone propionate (FP), is superior to AZE or FP alone for treatment of allergic rhinitis (AR). However, the precise anti-inflammatory mechanism of action of MP-AzeFlu has not been characterized. Objective: To investigate the anti-inflammatory effects of MP-AzeFlu compared with AZE or FP alone in an established in vitro model of eosinophilic inflammation. Methods: Nasal mucosal epithelial cells and peripheral blood eosinophils were obtained from human volunteers. Epithelial cells were stimulated with 10% fetal bovine serum (FBS) in the presence of MP-AzeFlu, AZE, or FP (1:102 to 1:105 dilution). Concentrations of interleukin (IL)-6, IL-8, and granulocyte-macrophage colony-stimulating factor (GM-CSF) were measured by ELISA. Eosinophils were incubated in 10% human epithelial cell-conditioned medium (HECM) and survival assessed by trypan blue dye exclusion. Results are expressed as mean ± SEM percentage secretion/survival compared with FBS/HECM (respectively). Results: FP and MP-AzeFlu (all dilutions) and AZE (1:102) significantly reduced IL-6 secretion and eosinophil survival compared with positive controls. At 1:102 dilution, IL-6 secretion was significantly lower with MP-AzeFlu (38.3 ± 4.2%, compared with FBS = 100%) than with AZE (76.1 ± 4.9%) or FP (53.0 ± 4.9%). At 1:102 dilution, eosinophil survival was significantly lower with MP-AzeFlu at day 3 (17.5 ± 3.0%) and day 4 (2.4 ± 1.4%, compared with HECM = 100%) than with AZE (day 3: 75.2 ± 7.2%; day 4: 44.0 ± 9.7%) or FP (day 3: 38.5 ± 3.5%; day 4: 14.6 ± 4.0%). Conclusion: Greater reductions in cytokine secretion and eosinophil survival observed with MP-AzeFlu in vitro may underlie MP-AzeFlu's superior clinical efficacy vs. AZE or FP alone observed in AR patients.
Note: Reproducció del document publicat a:
It is part of: Allergy, Asthma & Clinical Immunology, 2018, 14, 1, 86-NA
Related resource:
ISSN: 1710-1492
Appears in Collections:Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Files in This Item:
File Description SizeFormat 
12474_4140263_superior_effect_roca-ferrer_j_13223_2018_article_311.pdf990.03 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons